TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02202694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive behavior therapy
Description: This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
Study: NCT02635087

Intervention type: DEVICE
Intervention: miRNA tool
Description: patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
Study: NCT04701593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Sub-tenon irrigation 1cc
Study: NCT04652310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TFNA long nail (260-480mm)
Description: The long version of the TFN-advanced proximal femoral nailing system (TFNA)
Study: NCT01845948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parental training programme
Description: In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
Study: NCT02812212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
Study: NCT04510415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmutinib
Description: 600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
Study: NCT01416051

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olibra
Description: Fractionated palm oil and fractionated oat oil in the proportion of 95:5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100% milk fat
Study: NCT02812212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diuretic renography
Description: diuretic renography to measure the cortical transit time.
Study: NCT03682640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Monohydrate
Description: Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Solution for intravenous or subcutaneous use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietician support
Description: Dietary advice
Study: NCT02522845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II Compression Stockings (no specific device used)
Description: This study will be looking at the effect of compression therapy in patients having endothermal treatment for truncal incompetence of their varicose veins
Study: NCT05518552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lumbar traction
Description: Patient in the group were treated with manual traction
Study: NCT04434170

Intervention type: DRUG
Intervention: Sacubitril-Valsartan
Description: outpatients who start treatment with sacubitril/valsartan according to guidelines will andergo cardiopulmonary exercise testing evaluation
Study: NCT04572555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Treatment
Description: Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
Study: NCT01307020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: Dexketoprofen Trometamol low dose, oral film-coated table, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: Dexketoprofen Trometamol high dose, oral film-coated table, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride
Description: Tramadol Hydrochloride low dose, oral film-coated table, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride
Description: Tramadol Hydrochloride high dose, oral film-coated table, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg, oral film-coated table, once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral film-coated table, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol + Tramadol Hydrochloride
Description: DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol + Tramadol Hydrochloride
Description: DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol + Tramadol Hydrochloride
Description: DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol + Tramadol Hydrochloride
Description: DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
Study: NCT01952782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 112-121
Description: Subjects will receive up to 10 IV doses of kisspeptin 112-121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Subjects will receive one IV dose of naloxone followed by an IV infusion of naloxone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: Subjects will receive up to 10 doses of IV GnRH
Study: NCT05518552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone traction
Description: Patient in the group were placed on prone traction
Study: NCT02830984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EST+LBD+ENBD
Description: Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EST+LBD
Description: Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
Study: NCT00488631

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab 100 mg
Description: Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab 100 mg
Description: Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 200 mg
Description: Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
Study: NCT01073943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PicoPrep
Description: PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HalfLytely
Description: HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisacodyl
Description: Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
Study: NCT01152853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF00299804
Description: PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
Study: NCT02700529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ubenimex

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05878509

Intervention type: OTHER
Intervention: conducting questionnaires
Description: The patients were administered TSK, Pain Catastrophizing Scale (PCS), Beck Anxiety Inventory (BAI) by face to face interview technique.

Intervention type: OTHER
Intervention: assesment of the severity and pain
Description: The Modified Hand Injury Scoring System (MHISS) to determine the severity of the injury, and Visual Analog Scale (VAS) to evaluate perceived pain levels were used.
Study: NCT03232307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT01571492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L2 Paravertebral catheter nerve block
Description: A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Lumbar plexus nerve block
Description: A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
Study: NCT01126229

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules of placebo daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Resveratrol
Description: 2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Resveratrol
Description: 2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
Study: NCT01330290

Intervention type: DRUG
Intervention: Neupro®
Description: Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
Study: NCT01876589

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioresorbable vascular scaffold
Description: Drug eluting coronary stent, resorbable in 2-3 years

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Prime
Description: Drug eluting metallic stent
Study: NCT05077514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Cognitive Behavior Therapy
Description: Participants assigned to Group A were asked to participate in a talking session with a psychologist regarding thoughts about treatment. This session is designed to explore thoughts about behavioral health therapy for suicidality. The session was administered by phone, initially and again one month later. Participants discussed current functioning and their thoughts about seeking help with the goal of modifying thoughts about treatment. This phone session lasted approximately 45 to 60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: National Crisis Line
Description: Participants assigned to Group B received information about the VA's National Crisis Line.
Study: NCT03545243

Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole 40mg
Description: Peroral Pantoprazole 40mg once daily during 28 days

Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole 40mg
Description: Peroral Pantoprazole 40mg once daily during 28 days

Intervention type: OTHER
Group type: OTHER
Intervention: PPI withdrawal
Description: PPI withdrawal for 8 weeks
Study: NCT04938856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine tablet
Description: Lamotrigine 100 mg immediate release Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine tablet
Description: Lamotrigine 100 mg immediate release Tablet
Study: NCT02846558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequent Patient Interaction
Description: Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timing Restriction
Description: Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LoseIt! Smartphone Application
Description: Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoseIt! Smartphone Application
Description: Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
Study: NCT04998695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive pomace oil
Description: Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunflower oil
Description: Volunteers consumed during 4 weeks 45 g/d of sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
Study: NCT00564590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 4 mg of Melatonin once a day for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: omeprazole 20 mg once a day
Study: NCT04490707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
Study: NCT03624569

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bagel
Description: A bagel will be consumed daily for 2 weeks.
Study: NCT03349515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provodine-Iodine Solution
Description: Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes.
Study: NCT03624569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potato
Description: A potato will be consumed daily for 2 weeks.
Study: NCT03567655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farlutal tab. 500mg/ Pfizer
Description: Medroxyprogesterone Acetate
Study: NCT03943329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal targeting device technique of distal screw placement
Description: The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
Study: NCT00668005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5mg, 10mg or 20mg taken 1h before sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04299529

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: In-vitro urinary diagnostic test
Description: Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
Study: NCT00564590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo once a day
Study: NCT03604913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve sparing operation
Description: Aortic valve sparing instead of replacement during aortic root replacement
Study: NCT04299529

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In-vitro urinary diagnostic test
Description: Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
Study: NCT03349515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B will receive three drops in each eye of ophthalmic balanced salt solution.
Description: Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
Study: NCT02926339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens Against Tobacco Use presentation
Description: Students receive a series of 3 anti-tobacco presentations delivered by older peers
Study: NCT03333577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundArc
Description: non-surgical attachment method for wearing a bone conduction hearing system